Read our Recent Headlines

September 2 Biotech Update

The market looks bad again. Even though we are having a mini rally this morning, the sellers appear to be in control so far this week. I still think China.

Trevena Scores In Pain Study

Trevena Inc. (TRVN) presented positive Phase 2b results Monday August 31 from its TRV130 pain study. The primary endpoint of superior pain reduction compared to placebo was met, as well as.

ESPR Quick Note

Esperion shares have fallen over 8% today as The Medicines Co and Alnylam released early data on their RNAi candidate, ALN-PCSsc, targeting PCSK9. The drug was shown to efficiently and.

August 31 Biotech Update

Looks like a slightly lower start to the week. Macro still obviously matters but the size of the moves seems to be decreasing. I find it interesting that the weakness.

August 28 Biotech Update

I was busy for a day and the market does great but I come back and we have a gap lower. Sorry. In all seriousness, however, the snap back rally.

August 26 Biotech Update

The market had a rough day yesterday where the rally from the “lows” earlier in the week faded at the end of the day. That is never a good sign.

August 25 Biotech Update

Despite ending the day down significantly, it actually felt like a good day. I wanted to post a real quick and short note as from now on Tuesday and Thursday.


Quick Facts














Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!